Todos os estudos
RecrutamentoFASE3INTERVENCIONISTA

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where fat builds up in the liver, which can lead to inflammation and long-term scarring. The SYNERGY-Outcomes trial aims to find out if two newer medicines, tirzepatide and retatrutide, can protect the liver and prevent severe complications like liver failure. About 4,500 adults with signs of liver scarring will join this study. Participants are randomly chosen by a computer to receive regular doses of retatrutide, tirzepatide, or an inactive dummy treatment called a placebo. The main trial lasts around four and a half years and includes roughly 25 to 30 hospital visits for health checks, scans, and blood tests. Afterwards, participants may join an optional two-year extension where everyone receives an active medication.

Em resumo

Status
Recrutamento
Fase
FASE3
Patrocinador
Eli Lilly and Company
Meta de inscrição
4,500
Iniciar
15 Out 2025
Conclusão estimada
01 Aug 2032

Sobre o que é este estudo?

Metabolic dysfunction-associated steatotic liver disease, or MASLD for short, happens when extra fat builds up inside liver cells. For many people, this causes no noticeable symptoms at first. However, over time, the fat can irritate the liver, leading to inflammation and stiff scar tissue. If left unchecked, this scarring can slowly progress to severe liver damage, known as cirrhosis, or even liver failure.

Currently, the main treatments for MASLD involve lifestyle changes such as eating a balanced diet, exercising, and losing weight, but there are few approved medicines specifically designed to reverse or stop this damage. This clinical trial is testing two modern medications, tirzepatide and retatrutide. Both work by copying natural gut hormones that help control blood sugar, decrease appetite, and reduce fat stored in organs like the liver.

The main goal of the SYNERGY-Outcomes study is to see whether these medicines can stop major liver problems from developing in adults who already have significant liver fat and stiffness. By comparing these treatments against a dummy medicine (a placebo), researchers hope to find reliable evidence to help guide future care for thousands of people living with liver disease.

Pontos principais

  • The study tests whether tirzepatide or retatrutide can prevent severe liver complications in people with fatty liver disease (MASLD).
  • It is open to adults with liver fat and moderate scarring, measured using non-invasive scans and blood tests.
  • Participation lasts about four and a half years with roughly 25 to 30 clinic visits.
  • Participants are randomly assigned to receive tirzepatide, retatrutide, or an inactive placebo.
  • An optional two-year extension offers access to active medication for everyone who completes the main study.

Quem pode ser elegível?

This trial is for adults aged 18 and over who have a build-up of fat in their liver alongside early-to-moderate liver scarring (fibrosis). Doctors measure this using simple, non-invasive tests such as specialised ultrasound scans (like a FibroScan) and blood tests, rather than needing a surgical liver biopsy. To take part, you must also have a body mass index (BMI) of 25 or higher, which means carrying extra body weight.

You will not be able to join if your liver disease has already reached an advanced, failing stage—for example, if you have had fluid build-up in your tummy (ascites) or bleeding veins in your gullet. People with other liver conditions, such as viral hepatitis, cannot take part.

Additionally, the study is not suitable for people with type 1 diabetes, those whose blood sugar levels are very high (HbA1c over 10%), or anyone who has unintentionally lost more than 11 pounds (about 5 kg) in the three months before joining.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I am aged 18 or older.
  2. I have been told I have fatty liver disease (MASLD/NAFLD) with some liver stiffness or scarring.
  3. My body mass index (BMI) is 25 or higher.
  4. I do not have type 1 diabetes.
  5. I have not had serious liver failure complications (such as fluid build-up in the tummy or swollen veins in the gullet).
  6. I have not lost more than 11 pounds (5 kg) without trying in the last three months.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

Taking part in the study lasts around four and a half years (approximately 224 weeks). During this time, you will visit a specialist hospital clinic about 25 to 30 times. At these visits, doctors and nurses will check your general health, take blood and urine samples, and carry out periodic liver scans to see how your liver is responding.

You will be randomly assigned by a computer to receive weekly injections of either retatrutide, tirzepatide, or a dummy treatment (placebo). Neither you nor your study doctor can choose which one you receive. You will be shown how to give these injections yourself at home using an easy-to-use pen device. Once the main study ends, eligible participants can choose to join an optional two-year extension study, where everyone receives an active medicine.

Riscos e benefícios potenciais

A potential benefit is that your liver health and overall metabolism might improve if you receive an active medicine, and you will receive regular, detailed health monitoring from liver specialists throughout the trial. However, there is no guarantee of direct benefit, and you might receive the placebo. Possible risks include side effects typical of this type of medicine, such as nausea, indigestion, vomiting, diarrhoea, or constipation, especially when starting or increasing the dose. Taking part is completely voluntary, and you are free to leave the trial at any point without it affecting your usual NHS medical care.

Locations (563)

  • MFA Clinical Research
    Código postal verificado
    Tuscaloosa, United States· Recrutamento
  • The Institute for Liver Health II dba Arizona Clinical Trials - Chandler
    Código postal verificado
    Chandler, Estados Unidos· Recrutamento
  • Spectrum Research Institute
    Código postal verificado
    Gilbert, Estados Unidos· Recrutamento
  • The Institute for Liver Health II dba Arizona Liver Health - Peoria
    Código postal verificado
    Peoria, United States· Recrutamento
  • Epic Medical Research-Sun City
    Código postal verificado
    Sun City, Estados Unidos· Recrutamento
  • The Institute for Liver Health II dba Arizona Clinical Trials - Tucson
    Código postal verificado
    Tucson, Estados Unidos· Recrutamento
  • Gestão de Pesquisa Del Sol, LLC
    Código postal verificado
    Tucson, Estados Unidos· Recrutamento
  • Arkansas Gastroenterology - North Little Rock
    Código postal verificado
    North Little Rock, Estados Unidos· Recrutamento
  • San Fernando Valley Health Institute
    Código postal verificado
    Canoga Park, United States· Recrutamento
  • Ark Clinical Research - Fountain Valley
    Código postal verificado
    Fountain Valley, United States· Recrutamento
  • Fresno Clinical Research Center
    Código postal verificado
    Fresno, Estados Unidos· Recrutamento
  • UCSD - Altman Clinical and Translational Research Institute (ACTRI)
    Código postal verificado
    La Jolla, Estados Unidos· Recrutamento

Perguntas frequentes

What is MASLD?

MASLD stands for metabolic dysfunction-associated steatotic liver disease. It is the medical term for fat building up in the liver in people who may also have weight, cholesterol, or blood sugar concerns. It used to be commonly called non-alcoholic fatty liver disease (NAFLD).

O que é um placebo?

A placebo looks identical to the real medicine and is given the same way, but it contains no active ingredients. It helps researchers clearly see whether the real medicines work better than having no medication at all.

Will I have to pay for the treatment?

No. All study-related medicines, tests, and clinic appointments are provided free of charge, and trial organisers often help cover reasonable travel expenses to visits.

Do I have to have a liver biopsy to join?

No. This study uses non-invasive tests, such as simple blood tests and painless ultrasound-based scans, to check the fat and stiffness in your liver.

Can I leave the study early if I change my mind?

Yes. You can withdraw from the study at any time, for any reason, and your regular medical team will continue to look after your health as normal.

Como saber mais

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Master Protocol of Multiple Agents in Adults With Metaboli…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.